CL2014002523A1 - Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras - Google Patents

Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras

Info

Publication number
CL2014002523A1
CL2014002523A1 CL2014002523A CL2014002523A CL2014002523A1 CL 2014002523 A1 CL2014002523 A1 CL 2014002523A1 CL 2014002523 A CL2014002523 A CL 2014002523A CL 2014002523 A CL2014002523 A CL 2014002523A CL 2014002523 A1 CL2014002523 A1 CL 2014002523A1
Authority
CL
Chile
Prior art keywords
esophagitis
prematurity
retinopathy
piperidine
pyridine
Prior art date
Application number
CL2014002523A
Other languages
English (en)
Spanish (es)
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002523(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2014002523A1 publication Critical patent/CL2014002523A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Structure Of Transmissions (AREA)
CL2014002523A 2012-04-03 2014-09-24 Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras CL2014002523A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03

Publications (1)

Publication Number Publication Date
CL2014002523A1 true CL2014002523A1 (es) 2015-01-23

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002523A CL2014002523A1 (es) 2012-04-03 2014-09-24 Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras

Country Status (28)

Country Link
US (5) US20130261153A1 (enExample)
EP (3) EP4389217A3 (enExample)
JP (2) JP2015512432A (enExample)
KR (5) KR20210063481A (enExample)
CN (2) CN104220073A (enExample)
AU (1) AU2013245027B2 (enExample)
BR (1) BR112014023795B1 (enExample)
CA (1) CA2869269C (enExample)
CL (1) CL2014002523A1 (enExample)
CY (1) CY1123222T1 (enExample)
DK (1) DK2833884T3 (enExample)
EA (1) EA032263B1 (enExample)
ES (2) ES2987267T3 (enExample)
HR (1) HRP20201165T1 (enExample)
HU (1) HUE051648T2 (enExample)
IL (1) IL234262A (enExample)
IN (1) IN2014DN06989A (enExample)
LT (1) LT2833884T (enExample)
MX (1) MX2014011786A (enExample)
NZ (1) NZ628882A (enExample)
PH (1) PH12014502239A1 (enExample)
PL (1) PL2833884T3 (enExample)
PT (1) PT2833884T (enExample)
RS (1) RS60665B1 (enExample)
SI (1) SI2833884T1 (enExample)
SM (1) SMT202000499T1 (enExample)
WO (1) WO2013149986A1 (enExample)
ZA (1) ZA201406082B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US11045284B2 (en) 2016-11-24 2021-06-29 Kirishima Seiko Co., Ltd. Dental brace and method for attaching dental brace
NZ757769A (en) * 2017-04-05 2025-10-31 Alkahest Inc Methods and compositions for treating retina-associated disease using ccr3-inhibitors
WO2018187503A1 (en) 2017-04-05 2018-10-11 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
JP2020536929A (ja) * 2017-10-13 2020-12-17 アルカヘスト，インコーポレイテッド Ｃｃｒ３阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物
AU2019271122A1 (en) 2018-05-15 2020-11-12 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
CA3111433A1 (en) * 2018-09-26 2020-04-02 Alkahest, Inc. Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
JP2023529719A (ja) * 2020-06-11 2023-07-11 アルカヘスト，インコーポレイテッド Ｃｃｒ３阻害剤を使用した網膜関連疾患の転帰改善方法
US11957671B2 (en) 2021-11-01 2024-04-16 Alkahest, Inc. Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
IL151499A0 (en) * 2000-03-03 2003-04-10 Cambridge Antibody Tech Human antibodies against eotaxin and their use
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
CY1123222T1 (el) 2021-10-29
WO2013149986A1 (en) 2013-10-10
LT2833884T (lt) 2020-09-10
PH12014502239A1 (en) 2014-12-15
KR20200044988A (ko) 2020-04-29
US20200375971A1 (en) 2020-12-03
BR112014023795A2 (enExample) 2017-06-20
US20130261153A1 (en) 2013-10-03
KR20250133980A (ko) 2025-09-09
KR20210063481A (ko) 2021-06-01
HUE051648T2 (hu) 2021-03-29
US20170319567A1 (en) 2017-11-09
US20160081998A1 (en) 2016-03-24
JP2015512432A (ja) 2015-04-27
EA201401083A1 (ru) 2015-03-31
IN2014DN06989A (enExample) 2015-04-10
EP3763369B1 (en) 2024-02-28
AU2013245027B2 (en) 2017-10-12
US20150099783A1 (en) 2015-04-09
SI2833884T1 (sl) 2020-10-30
DK2833884T3 (da) 2020-08-10
NZ628882A (en) 2016-05-27
KR20220132012A (ko) 2022-09-29
MX2014011786A (es) 2014-12-05
PT2833884T (pt) 2020-08-26
RS60665B1 (sr) 2020-09-30
CN104220073A (zh) 2014-12-17
AU2013245027A1 (en) 2014-09-11
ES2987267T3 (es) 2024-11-14
CN110384699A (zh) 2019-10-29
KR20140144200A (ko) 2014-12-18
EP2833884A1 (en) 2015-02-11
EP4389217A2 (en) 2024-06-26
EP4389217A3 (en) 2024-08-28
CA2869269C (en) 2020-06-30
PL2833884T3 (pl) 2020-11-02
ES2811554T3 (es) 2021-03-12
BR112014023795B1 (pt) 2021-09-08
EA032263B1 (ru) 2019-05-31
CA2869269A1 (en) 2013-10-10
SMT202000499T1 (it) 2020-11-10
ZA201406082B (en) 2019-01-30
EP3763369A1 (en) 2021-01-13
JP2018080183A (ja) 2018-05-24
BR112014023795A8 (pt) 2017-10-10
IL234262A (en) 2017-10-31
EP2833884B1 (en) 2020-05-20
HRP20201165T1 (hr) 2020-12-11

Similar Documents

Publication Publication Date Title
CL2014002523A1 (es) Compuestos derivados de piridina , piperidina y pirrol sustituidos, inhibidores de ccr3; uso para el tratamiento de enfermedades seleccionadas de degeneracion macular relacionada con la edad, retinopatia del prematuro, oclusion venosa retinal central, poliposis nasal, esofagitis y/o gastroenteritis eosinofilica, entre otras
CO2017012267A2 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
IL267997A (en) Preparations, formulations and methods for treating eye diseases
BR112015010360A8 (pt) antagonistas de il-6 e utilização dos mesmos.
CL2016000060A1 (es) Derivados piperidinil indol y su uso como inhibidores factor de complemento b.
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
CO2017000399A2 (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
MX389256B (es) Compuestos heterociclicos y usos de los mismos.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
DK3385262T3 (da) 4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
DK3350180T3 (da) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2-onderivater som selektive modulatorer af ataxia telangiectasia muteret (atm) kinase til behandling af cancer
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
PT3069720T (pt) Composição farmacológica que contém derivados de glutarimida, e a aplicação da mesma no tratamento de doenças eosinofílicas
KR102183910B9 (ko) 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
MX2017016149A (es) Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa.
CL2015002835A1 (es) Nuevos derivados de piridina
GEP20166489B (en) 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
CL2012003637A1 (es) Compuestos derivados de quinazolina o triazolopiridina sustituidos, inhibidores selectivos de tirosina quinasa; medicamento; composicion farmaceutica; y su uso para tratar, prevenir o mejorar edema retiniano/macular, degeneración macular relacionada con la edad y derrame vascular retiniano relacionado con isquemia, entre otras.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CL2015001187A1 (es) Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.